SGLT-1 and SGLT-2 proteins
May 01, 2019
European Commission gives a nod to Zynquista for type 1 diabetes in adults
The European Commission approved Zynquista (sotagliflozin) as a new treatment for people with type 1 diabetes. Zynquista is an oral tablet which prevents the SGLT-1 and SGLT-2 proteins that impact how the intestines and kidneys absorb and glucose that will result in better diabetes control. Sanofi is collaborating ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
